Document Detail


Pathological changes in tight junctions and potential applications into therapies.
MedLine Citation:
PMID:  22414542     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Epithelial cells are pivotal in the separation of the body from the outside environment. Orally administered drugs must pass across epithelial cell sheets, and most pathological organisms invade the body through epithelial cells. Tight junctions (TJs) are sealing complexes between adjacent epithelial cells. Modulation of TJ components is a potent strategy for increasing absorption. Inflammation often causes disruption of the TJ barrier. Molecular imaging technology has enabled elucidation of the dynamics of TJs. Molecular pathological analysis has shown the relationship between TJ components and molecular pathological conditions. In this article, we discuss TJ-targeted drug development over the past 2 years.
Authors:
Azusa Takahashi; Masuo Kondoh; Hidehiko Suzuki; Kiyohito Yagi
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-5
Journal Detail:
Title:  Drug discovery today     Volume:  -     ISSN:  1878-5832     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9604391     Medline TA:  Drug Discov Today     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012. Published by Elsevier Ltd.
Affiliation:
Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka 565-0871, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Positive components of mental health provide significant protection against likelihood of falling in...
Next Document:  Catechins containing a galloyl moiety as potential anti-HIV-1 compounds.